Amgen Acquires Scholar Rock for $792M
Ticker: SRRK · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1727196
Sentiment: bullish
Topics: acquisition, merger, biotech
Related Tickers: AMGN
TL;DR
Amgen buying Scholar Rock for $792M cash, deal expected H1 2025.
AI Summary
Scholar Rock Holding Corp. announced on January 14, 2025, that it has entered into a definitive agreement to be acquired by Amgen Inc. for $3.75 per share in cash, totaling approximately $792 million. This acquisition is expected to close in the first half of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by Amgen, a major biotechnology company, signifies a significant consolidation in the biotech sector and highlights the value of Scholar Rock's pipeline, potentially impacting the development of new treatments.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and regulatory approvals could introduce delays or complications.
Key Numbers
- $792 million — Acquisition Value (Total cash consideration for Scholar Rock)
- $3.75 — Per Share Price (Cash amount each Scholar Rock shareholder will receive)
Key Players & Entities
- Scholar Rock Holding Corp. (company) — Company being acquired
- Amgen Inc. (company) — Acquiring company
- $3.75 (dollar_amount) — Per share acquisition price
- $792 million (dollar_amount) — Total acquisition value
- January 14, 2025 (date) — Date of announcement
- first half of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition?
The total value of the acquisition is approximately $792 million.
What is the per share price for Scholar Rock shareholders?
Scholar Rock shareholders will receive $3.75 per share in cash.
Who is acquiring Scholar Rock?
Amgen Inc. is acquiring Scholar Rock Holding Corp.
When is the acquisition expected to close?
The acquisition is expected to close in the first half of 2025.
What is the filing date of this 8-K?
This 8-K filing was made on January 14, 2025.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-14 12:30:34
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share SRRK The Nasdaq Global Se
Filing Documents
- srrk-20250114x8k.htm (8-K) — 36KB
- srrk-20250114xex99d1.htm (EX-99.1) — 52KB
- srrk-20250114xex99d1g001.jpg (GRAPHIC) — 128KB
- srrk-20250114xex99d1g002.jpg (GRAPHIC) — 364KB
- srrk-20250114xex99d1g003.jpg (GRAPHIC) — 160KB
- srrk-20250114xex99d1g004.jpg (GRAPHIC) — 181KB
- srrk-20250114xex99d1g005.jpg (GRAPHIC) — 128KB
- srrk-20250114xex99d1g006.jpg (GRAPHIC) — 133KB
- srrk-20250114xex99d1g007.jpg (GRAPHIC) — 120KB
- srrk-20250114xex99d1g008.jpg (GRAPHIC) — 144KB
- srrk-20250114xex99d1g009.jpg (GRAPHIC) — 156KB
- srrk-20250114xex99d1g010.jpg (GRAPHIC) — 161KB
- srrk-20250114xex99d1g011.jpg (GRAPHIC) — 130KB
- srrk-20250114xex99d1g012.jpg (GRAPHIC) — 92KB
- srrk-20250114xex99d1g013.jpg (GRAPHIC) — 82KB
- srrk-20250114xex99d1g014.jpg (GRAPHIC) — 138KB
- srrk-20250114xex99d1g015.jpg (GRAPHIC) — 120KB
- srrk-20250114xex99d1g016.jpg (GRAPHIC) — 133KB
- srrk-20250114xex99d1g017.jpg (GRAPHIC) — 117KB
- srrk-20250114xex99d1g018.jpg (GRAPHIC) — 127KB
- srrk-20250114xex99d1g019.jpg (GRAPHIC) — 87KB
- srrk-20250114xex99d1g020.jpg (GRAPHIC) — 171KB
- srrk-20250114xex99d1g021.jpg (GRAPHIC) — 133KB
- srrk-20250114xex99d1g022.jpg (GRAPHIC) — 159KB
- srrk-20250114xex99d1g023.jpg (GRAPHIC) — 140KB
- srrk-20250114xex99d1g024.jpg (GRAPHIC) — 134KB
- srrk-20250114xex99d1g025.jpg (GRAPHIC) — 119KB
- srrk-20250114xex99d1g026.jpg (GRAPHIC) — 125KB
- srrk-20250114xex99d1g027.jpg (GRAPHIC) — 130KB
- srrk-20250114xex99d1g028.jpg (GRAPHIC) — 172KB
- srrk-20250114xex99d1g029.jpg (GRAPHIC) — 158KB
- srrk-20250114xex99d1g030.jpg (GRAPHIC) — 96KB
- srrk-20250114xex99d1g031.jpg (GRAPHIC) — 115KB
- srrk-20250114xex99d1g032.jpg (GRAPHIC) — 97KB
- srrk-20250114xex99d1g033.jpg (GRAPHIC) — 136KB
- srrk-20250114xex99d1g034.jpg (GRAPHIC) — 162KB
- srrk-20250114xex99d1g035.jpg (GRAPHIC) — 24KB
- 0001558370-25-000184.txt ( ) — 6770KB
- srrk-20250114.xsd (EX-101.SCH) — 3KB
- srrk-20250114_lab.xml (EX-101.LAB) — 16KB
- srrk-20250114_pre.xml (EX-101.PRE) — 10KB
- srrk-20250114x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. A copy of the presentation that will be used by management of Scholar Rock Holding Corporation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 is being furnished as Exhibit 99.1 to this report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Scholar Rock Holding Corporation Corporate Presentation dated January 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Scholar Rock Holding Corporation Date: January 14, 2025 By: /s/ Junlin Ho Junlin Ho General Counsel & Corporate Secretary